{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:55:19Z","timestamp":1790153719566,"version":"4.0.1"},"reference-count":84,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la Ricerca sul Cancro ETS","doi-asserted-by":"crossref","award":["MFAG-27142"],"award-info":[{"award-number":["MFAG-27142"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["PE00000019 Heal Italia"],"award-info":[{"award-number":["PE00000019 Heal Italia"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"crossref","award":["2022JEBP88"],"award-info":[{"award-number":["2022JEBP88"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Drug repositioning, also known as drug repurposing, represents a cost-effective and time-efficient approach to accelerate the development of novel therapies for colorectal cancer (CRC), the third most common cancer worldwide, with an estimated two million new cases and nearly one million deaths annually. This review aims to critically evaluate how existing non-oncologic drugs can be repositioned to exploit key metabolic vulnerabilities of CRC cells. Targeting cancer cell metabolism offers a unique therapeutic advantage, as it disrupts the bioenergetic and biosynthetic processes that sustain tumor growth, adaptation, and resistance to therapy. Specifically, we examine the mechanisms through which antidiabetic, cardiovascular, anti-inflammatory, antidepressant, and anthelmintic agents interfere with glycolysis, oxidative phosphorylation (OxPhos), and mitochondrial bioenergetics\u2014metabolic circuits central to CRC progression and recurrence. By integrating recent mechanistic, preclinical, and clinical findings, we highlight how these repurposed drugs converge on major metabolic regulators, including the AMPK\/mTOR signaling pathways, and how they can potentiate the efficacy of standard chemotherapies and immunotherapies. Furthermore, we discuss the translational challenges that must be addressed to move these compounds into clinical use. Collectively, this review underscores the therapeutic potential of targeting CRC metabolism through drug repositioning as a promising avenue toward more effective and personalized treatment strategies.<\/jats:p>","DOI":"10.3390\/cells14241968","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T11:17:27Z","timestamp":1765451847000},"page":"1968","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting Cancer Cell Energy Metabolism in Colorectal Cancer: Opportunities and Challenges from Drug Repositioning"],"prefix":"10.3390","volume":"14","author":[{"given":"Lorenzo","family":"Tomassini","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-3672","authenticated-orcid":false,"given":"Teresa","family":"Pacifico","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-9076","authenticated-orcid":false,"given":"Giovanni","family":"Monteleone","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"},{"name":"Gastroenterology Unit, Policlinico Universitario Tor Vergata, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6354-2443","authenticated-orcid":false,"given":"Carmine","family":"Stolfi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7380-0269","authenticated-orcid":false,"given":"Federica","family":"Laudisi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/gutjnl-2014-309086","article-title":"Colorectal cancer screening: A global overview of existing programmes","volume":"64","author":"Schreuders","year":"2015","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/14712598.2018.1445222","article-title":"Results and challenges of immune checkpoint inhibitors in colorectal cancer","volume":"18","author":"Emambux","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrc.2016.126","article-title":"Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer","volume":"17","author":"Dienstmann","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330\u2013337.","DOI":"10.1038\/nature11252"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1038\/emm.2013.85","article-title":"Cancer cell metabolism: Implications for therapeutic targets","volume":"45","author":"Jang","year":"2013","journal-title":"Exp. Mol. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13045-022-01358-5","article-title":"Warburg effect in colorectal cancer: The emerging roles in tumor microenvironment and therapeutic implications","volume":"15","author":"Zhong","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_14","first-page":"309","article-title":"On the Origin of Cancer Cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science (1979)"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: Insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the Intersections between Metabolism and Cancer Biology","volume":"168","author":"DeBerardinis","year":"2017","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","article-title":"Mitochondrial TCA cycle metabolites control physiology and disease","volume":"11","author":"Chandel","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.trecan.2024.09.010","article-title":"Mitochondrial DNA damage, repair, and replacement in cancer","volume":"11","author":"Vodicka","year":"2025","journal-title":"Trends Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1002\/1878-0261.13291","article-title":"Mitochondrial DNA mutations in ageing and cancer","volume":"16","author":"Smith","year":"2022","journal-title":"Mol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.freeradbiomed.2016.04.025","article-title":"Oncometabolites: Unconventional triggers of oncogenic signalling cascades","volume":"100","author":"Sciacovelli","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25669","DOI":"10.1038\/srep25669","article-title":"Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas","volume":"6","author":"Isono","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial Metabolism as a Target for Cancer Therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s11658-025-00710-0","article-title":"Old drugs, new challenges: Reassigning drugs for cancer therapies","volume":"30","author":"Czechowicz","year":"2025","journal-title":"Cell Mol. Biol. Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/clpt.2009.295","article-title":"Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs","volume":"87","author":"DiMasi","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"103684","DOI":"10.1016\/j.drudis.2023.103684","article-title":"Repurposing drugs targeting metabolic diseases for cancer therapeutics","volume":"28","author":"Pillai","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_29","first-page":"5625","article-title":"Dual anticancer role of metformin: An old drug regulating AMPK dependent\/independent pathways in metabolic, oncogenic\/tumorsuppresing and immunity context","volume":"11","author":"Vucicevic","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1158\/1078-0432.CCR-10-2243","article-title":"Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth","volume":"17","author":"Rocha","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15992","DOI":"10.1038\/s41598-017-16149-z","article-title":"Metformin transiently inhibits colorectal cancer cell proliferation as a result of either AMPK activation or increased ROS production","volume":"7","author":"Mogavero","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1073\/pnas.1221055110","article-title":"Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth","volume":"110","author":"Hirsch","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Orang, A., Marri, S., McKinnon, R.A., Petersen, J., and Michael, M.Z. (2024). Restricting Colorectal Cancer Cell Metabolism with Metformin: An Integrated Transcriptomics Study. Cancers, 16.","DOI":"10.3390\/cancers16112055"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1038\/s41598-022-06587-9","article-title":"A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells","volume":"12","author":"Orang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113214","DOI":"10.1016\/j.biopha.2022.113214","article-title":"Cytotoxic effect of metformin on butyrate-resistant PMF-K014 colorectal cancer spheroid cells","volume":"151","author":"Nittayaboon","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1111\/j.1349-7006.2008.00933.x","article-title":"Metformin suppresses intestinal polyp growth in Apc Min\/+ mice","volume":"99","author":"Tomimoto","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mc.20637","article-title":"Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase","volume":"49","author":"Hosono","year":"2010","journal-title":"Mol. Carcinog."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s44276-023-00022-w","article-title":"Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular traps","volume":"1","author":"Saito","year":"2023","journal-title":"BJC Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1507\/endocrj.EJ15-0396","article-title":"Effect of dapagliflozin on colon cancer cell [Rapid Communication]","volume":"62","author":"Saito","year":"2015","journal-title":"Endocr. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/iub.2454","article-title":"The mechanism of sitagliptin inhibition of colorectal cancer cell lines\u2019 metastatic functionalities","volume":"73","author":"Martins","year":"2021","journal-title":"IUBMB Life"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shih, J.-W., Wu, A.T.H., Mokgautsi, N., Wei, P.-L., and Huang, Y.-J. (2024). Preclinical Repurposing of Sitagliptin as a Drug Candidate for Colorectal Cancer by Targeting CD24\/CTNNB1\/SOX4-Centered Signaling Hub. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010609"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e23796","DOI":"10.1002\/jbt.23796","article-title":"Sitagliptin synergizes 5-fluorouracil efficacy in colon cancer cells through MDR1-mediated flux impairment and down regulation of NF\u03baB2 and p-AKT survival proteins","volume":"38","author":"Eisa","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"ref_44","first-page":"2223","article-title":"Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells","volume":"5","author":"Agarwal","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Huang, X., Liang, N., Zhang, F., Lin, W., and Ma, W. (2024). Lovastatin-Induced Mitochondrial Oxidative Stress Leads to the Release of mtDNA to Promote Apoptosis by Activating cGAS-STING Pathway in Human Colorectal Cancer Cells. Antioxidants, 13.","DOI":"10.3390\/antiox13060679"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/j.1349-7006.2010.01579.x","article-title":"Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL\/KsJ- db\/db obese mice","volume":"101","author":"Yasuda","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12935-025-03712-2","article-title":"Repurposing pitavastatin and atorvastatin to overcome chemoresistance of metastatic colorectal cancer under high glucose conditions","volume":"25","author":"Cheng","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3892\/ol.2016.4569","article-title":"Statin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activation","volume":"12","author":"Jang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-017-3337-2","article-title":"The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway","volume":"80","author":"Pan","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/mc.21968","article-title":"Cellular location and expression of Na +, K + -ATPase \u03b1 subunits affect the anti-proliferative activity of oleandrin","volume":"53","author":"Yang","year":"2014","journal-title":"Mol. Carcinog."},{"key":"ref_51","first-page":"3741","article-title":"Modulation of mitochondrial apoptosis by \u03b22-adrenergic receptor blockage in colorectal cancer after radiotherapy: An in-vivo and in-vitro study","volume":"13","author":"Shi","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Barathova, M., Grossmannova, K., Belvoncikova, P., Kubasova, V., Simko, V., Skubla, R., Csaderova, L., and Pastorek, J. (2020). Impairment of Hypoxia-Induced CA IX by Beta-Blocker Propranolol\u2014Impact on Progression and Metastatic Potential of Colorectal Cancer Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228760"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40170-023-00318-y","article-title":"Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition","volume":"11","author":"Holt","year":"2023","journal-title":"Cancer Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3892\/mmr.2016.5449","article-title":"Aspirin inhibits glucose-6-phosphate dehydrogenase activity in HCT 116 cells through acetylation: Identification of aspirin-acetylated sites","volume":"14","author":"Ai","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_55","first-page":"1273","article-title":"Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets","volume":"39","author":"Marimuthu","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1053\/j.gastro.2012.02.050","article-title":"Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells","volume":"142","author":"Din","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/1940-6207.CAPR-20-0014","article-title":"Metabolomics Analysis of Aspirin\u2019s Effects in Human Colon Tissue and Associations with Adenoma Risk","volume":"13","author":"Barry","year":"2020","journal-title":"Cancer Prev. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1158\/1940-6207.CAPR-21-0555","article-title":"Plasma Metabolomics Analysis of Aspirin Treatment and Risk of Colorectal Adenomas","volume":"15","author":"Barry","year":"2022","journal-title":"Cancer Prev. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13014-024-02399-5","article-title":"The radiation- and chemo-sensitizing capacity of diclofenac can be predicted by a decreased lactate metabolism and stress response","volume":"19","author":"Schwab","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Han, Y., Chen, P., Zhang, Y., Lu, W., Ding, W., Luo, Y., Wen, S., Xu, R., Liu, P., and Huang, P. (2019). Synergy between Auranofin and Celecoxib against Colon Cancer In Vitro and In Vivo through a Novel Redox-Mediated Mechanism. Cancers, 11.","DOI":"10.3390\/cancers11070931"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"172441","DOI":"10.1016\/j.ejphar.2019.172441","article-title":"Fluoxetine selectively induces p53-independent apoptosis in human colorectal cancer cells","volume":"857","author":"Marcinkute","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kannen, V., Hintzsche, H., Zanette, D.L., Silva, W.A., Garcia, S.B., Waaga-Gasser, A.M., and Stopper, H. (2012). Antiproliferative Effects of Fluoxetine on Colon Cancer Cells and in a Colonic Carcinogen Mouse Model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050043"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.cellsig.2015.05.008","article-title":"Oncostatic effects of fluoxetine in experimental colon cancer models","volume":"27","author":"Kannen","year":"2015","journal-title":"Cell. Signal."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"He, L., Tian, Y., Liu, Q., Bao, J., and Ding, R.-B. (2024). Antidepressant Sertraline Synergistically Enhances Paclitaxel Efficacy by Inducing Autophagy in Colorectal Cancer Cells. Molecules, 29.","DOI":"10.3390\/molecules29163733"},{"key":"ref_65","first-page":"277","article-title":"Evaluation of the potential anti-cancer activity of the antidepressant sertraline in human colon cancer cell lines and in colorectal cancer-xenografted mice","volume":"33","author":"Zolokov","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"126464","DOI":"10.1016\/j.saa.2025.126464","article-title":"Exploring the Impact of Citalopram on Human Colon Cells: Insights into Antidepressant Action Beyond the Brain","volume":"343","year":"2025","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.chembiol.2023.05.009","article-title":"TRIM21 is a druggable target for the treatment of metastatic colorectal cancer through ubiquitination and activation of MST2","volume":"30","author":"Liu","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2406936121","DOI":"10.1073\/pnas.2406936121","article-title":"TRIM21 induces selective autophagic degradation of c-Myc and sensitizes regorafenib therapy in colorectal cancer","volume":"121","author":"Ye","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"Chen","year":"2018","journal-title":"Cell. Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/BCJ20180385","article-title":"Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy","volume":"476","author":"Wang","year":"2019","journal-title":"Biochem. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-017-0092-6","article-title":"Effect of mitochondrial uncouplers niclosamide ethanolamine (NEN) and oxyclozanide on hepatic metastasis of colon cancer","volume":"9","author":"Alasadi","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8943","DOI":"10.1038\/s41598-022-12519-4","article-title":"Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma","volume":"12","author":"Ek","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13046-019-1303-z","article-title":"Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy","volume":"38","author":"Lin","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3892\/ol.2024.14691","article-title":"Anticancer role of flubendazole: Effects and molecular mechanisms (Review)","volume":"28","author":"Xing","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12032-021-01472-3","article-title":"Pyrvinium pamoate inhibits cell proliferation through ROS-mediated AKT-dependent signaling pathway in colorectal cancer","volume":"38","author":"Zheng","year":"2021","journal-title":"Med. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1158\/1535-7163.MCT-20-0652","article-title":"The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria","volume":"20","author":"Schultz","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"25759","DOI":"10.1038\/s41598-025-10768-7","article-title":"Metformin\u2019s impact on tumor regression grade in diabetic patients with rectal cancer undergoing neoadjuvant chemoradiotherapy","volume":"15","author":"Lin","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4143\/crt.2018.379","article-title":"A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients","volume":"51","author":"Kim","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s10637-015-0285-8","article-title":"Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients","volume":"33","author":"Baas","year":"2015","journal-title":"Investig. New Drugs"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00280-008-0913-5","article-title":"Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: A multicenter phase II study","volume":"64","author":"Lee","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/j.annonc.2023.04.337","article-title":"P-281 Safety analysis and preliminary clinical results of REPROGRAM-01 phase II study evaluating regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer","volume":"34","author":"Borg","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"viii200","DOI":"10.1093\/annonc\/mdy281.148","article-title":"Induction chemotherapy plus chemoradiotherapy with or without aspirin in high risk rectal cancer (ICAR)","volume":"29","author":"Souza","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Nenkov, M., Ma, Y., Ga\u00dfler, N., and Chen, Y. (2021). Metabolic Reprogramming of Colorectal Cancer Cells and the Microenvironment: Implication for Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126262"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Cao, Q., Yang, M., and Chen, M. (2025). Metabolic interactions: How gut microbial metabolites influence colorectal cancer. Front. Microbiol., 16.","DOI":"10.3389\/fmicb.2025.1611698"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/24\/1968\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:23:20Z","timestamp":1765603400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/24\/1968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":84,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["cells14241968"],"URL":"https:\/\/doi.org\/10.3390\/cells14241968","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}